LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Atvērts

3.41 -0.58

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.22

Max

3.44

Galvenie mērījumi
By Trading Economics
Ienākumi	5.5M -28M
Pārdošana	8.2M 13M
Peļņas marža	-208.694
Darbinieki	172
EBITDA	8.7M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+352.21% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-66M 188M
Iepriekšējā atvēršanas cena	3.99
Iepriekšējā slēgšanas cena	3.41

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. febr. 22:31 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026. g. 18. febr. 22:18 UTC

Peļņas

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026. g. 18. febr. 22:11 UTC

Peļņas

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026. g. 18. febr. 21:52 UTC

Peļņas

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026. g. 18. febr. 23:56 UTC

Tirgus saruna

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026. g. 18. febr. 23:34 UTC

Tirgus saruna

Peļņas

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026. g. 18. febr. 23:33 UTC

Tirgus saruna

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026. g. 18. febr. 23:32 UTC

Tirgus saruna

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026. g. 18. febr. 22:45 UTC

Peļņas

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026. g. 18. febr. 22:44 UTC

Tirgus saruna

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q EPS $1.18 >NTR.T

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q Sales $5.34B >NTR.T

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q EPS $1.07 >PAAS

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q Rev $1.18B >PAAS

2026. g. 18. febr. 22:30 UTC

Peļņas

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026. g. 18. febr. 22:29 UTC

Peļņas

Kinross Gold 4Q EPS 75c >K.T

2026. g. 18. febr. 22:22 UTC

Peļņas

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026. g. 18. febr. 22:22 UTC

Tirgus saruna

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026. g. 18. febr. 22:16 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026. g. 18. febr. 22:05 UTC

Peļņas

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026. g. 18. febr. 22:03 UTC

Peļņas

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Sales $929M >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Adj EPS 67c >KGC

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Sales $2.02B >KGC

2026. g. 18. febr. 21:56 UTC

Peļņas

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026. g. 18. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

352.21% augšup

Prognoze 12 mēnešiem

Vidējais 15.33 USD 352.21%

Augstākais 25 USD

Zemākais 10 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.